New studies indicate that GLP-1 medications, widely used for type 2 diabetes and obesity, may carry increased risks for bone health, particularly in older patients. Research published in the Journal of Clinical Endocrinology & Metabolism found an 11% higher risk of fragility fractures in older adults with type 2 diabetes initiating GLP-1s compared to those on other diabetes treatments.
Fragility fractures, often associated with osteoporosis, can lead to serious health consequences for seniors. The study observed over 46,000 adults aged 65 and older, revealing a statistically significant increase in fracture risk among GLP-1 users.
Further analysis presented at the American Academy of Orthopaedic Surgeons' meeting indicated a 29% higher relative risk of osteoporosis and a slight increase in gout among adults with obesity and type 2 diabetes using GLP-1s. Osteomalacia, a softening of the bones, was also observed at higher rates.
Experts suggest potential causes include rapid weight loss, reduced bone density due to less mechanical load on the skeleton, and decreased intake of crucial nutrients like calcium and vitamin D. Increased uric acid levels from tissue breakdown may also contribute to gout.
Despite these findings, experts emphasize that the benefits of GLP-1 medications for blood sugar control, weight loss, and cardiovascular health should not be overlooked. They recommend bone density screenings before initiating treatment in older patients, alongside adequate nutrition and resistance training to support bone and muscle health.